Navigation Links
MAP Pharmaceuticals Submits New Drug Application to FDA for LEVADEX® Orally Inhaled Migraine Drug
Date:5/26/2011

MOUNTAIN VIEW, Calif., May 26, 2011 /PRNewswire/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) today announced that it has submitted a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for LEVADEX® orally inhaled migraine drug for the potential acute treatment of migraine in adults. According to the National Headache Foundation, approximately 30 million people in the United States suffer from migraine, a debilitating neurological disorder. Common symptoms of migraine include recurrent headaches, nausea, phonophobia (sensitivity to sound) and photophobia (sensitivity to light).

"This NDA submission marks a major corporate milestone for MAP Pharmaceuticals and brings us one step closer to our goal of providing the underserved migraine patient population with a potential new treatment option," said Timothy S. Nelson, president and chief executive officer of MAP Pharmaceuticals. "Our comprehensive development program evaluated LEVADEX in approximately 1,000 patients for up to one year, treating nearly 10,000 migraines. If approved by the FDA, LEVADEX could potentially provide a new treatment option for migraine sufferers, including the millions of patients whose migraines are not well treated today."

The 505(b)(2) NDA submission is based on a comprehensive development program for LEVADEX, and includes efficacy and safety data from the Phase 3 FREEDOM-301 clinical trial that has been presented at scientific conferences and was recently published in Headache: The Journal of Head and Face Pain. In the FREEDOM-301 trial, patients self-administered LEVADEX at home using the Company's proprietary TEMPO® inhaler. LEVADEX contains a novel formulation of dihydroergotamine (DHE).  Patients taking LEVADEX in this pivotal trial had statistically significant improvement at two hours compared to patients on placebo for all four c
'/>"/>

SOURCE MAP Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Watson Acquires Specifar Pharmaceuticals
2. Auxilium Pharmaceuticals, Inc. Updates Launch Progress of XIAPEX® in EU
3. BioMarin to Present at the UBS Global Specialty Pharmaceuticals Conference
4. Watson Pharmaceuticals Announces New Research Showing RAPAFLO(R) (silodosin) Improves Outcomes for Chronic Prostatitis/Chronic Pelvic Pain Syndrome
5. Auxilium Pharmaceuticals, Inc. Announces First Quarter 2011 Financial Results and Operational Highlights
6. Inovio Pharmaceuticals Reports Long-Term Immune Responses from Therapeutic Cervical Dysplasia and Cancer DNA Vaccine
7. Vanda Pharmaceuticals Reports First Quarter 2011 Results
8. MAP Pharmaceuticals Reports First Quarter of 2011 Financial Results
9. Anadys Pharmaceuticals to Report First Quarter 2011 Financial Results
10. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2011 Financial Results
11. Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... (PRWEB) January 15, 2014 This webinar ... nonclinical and clinical safety assessment in biosimilars. , Regulatory ... for biosimilar drug development, however the complex nature of ... quality, safety and efficacy extremely challenging. Based on the ...
(Date:1/15/2014)... (PRWEB) January 15, 2014 The Microcompetition with ... major disease. One of these latent viruses is the Epstein ... arthritis (RA). Rheumatoid arthritis (RA) is a chronic inflammatory disease ... a study found that RA patients have high concentrations of ...
(Date:1/15/2014)... 15, 2014 AudioNotch is the internet's ... for the treatment of tinnitus. Patients listen to sound ... over a period of weeks to months, their tinnitus volume ... two forms: Notched Music and Notched White Noise. Now, AudioNotch ...
(Date:1/14/2014)... 14, 2014 Histogen, Inc., a regenerative ... cells grown under simulated embryonic conditions, today announced that ... Suneva Medical, Inc. for physician-dispensed aesthetic products containing Histogen’s ... This agreement is an amendment to the existing license ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3
... today by CSL Behring at the 2012 ... that a balanced, human 4-factor prothrombin complex concentrate (PCC) ... in stopping bleeding in patients receiving vitamin K antagonist ... frozen plasma is the standard treatment for warfarin reversal. ...
... A new bio-inspired approach to synthesising polymers will offer unprecedented ... nanomedicine, researchers say. In a study published last week ... the University of New South Wales in Sydney and the ... method of polymer synthesis based on a combination of segregation ...
... a team including scientists from the National Institute of Standards ... different properties depending on the method by which they are ... explore the best way of creating these films, which are ... devices. Thin films spread atop a surface have many ...
Cached Biology Technology:CSL Behring Data Shows 4-Factor Prothrombin Complex Concentrate Is As Effective and a More Rapid Treatment for Vitamin K Antagonist Reversal Than Current Standard of Care 2CSL Behring Data Shows 4-Factor Prothrombin Complex Concentrate Is As Effective and a More Rapid Treatment for Vitamin K Antagonist Reversal Than Current Standard of Care 3CSL Behring Data Shows 4-Factor Prothrombin Complex Concentrate Is As Effective and a More Rapid Treatment for Vitamin K Antagonist Reversal Than Current Standard of Care 4Bio-inspired polymer synthesis enhances structure control 2Fabrication method can affect the use of block copolymer thin films 2
(Date:4/23/2014)... HUNTSVILLE, TX (4/23/14) -- Researchers have found evidence ... risk factors that increase aggressive behavior in children, ... that not all children exposed to prenatal smoking ... others will not," said Brian Boutwell, Assistant Professor ... Justice and senior author on the study. ...
(Date:4/23/2014)... as an antimicrobial ingredient in soaps, toothpastes and other ... new evidence that appears to support these worries. Their ... in Toxicology , found that triclosan, as well as ... human breast cancer cells in lab dishes and breast ... note that hormonal imbalances seem to play a role ...
(Date:4/23/2014)... to date of the family of bacteria that ... strategies and reveals surprising findings about the bacteria,s ... public health strategies to control this respiratory disease, ... Genomic analysis of 343 strains of the ... collected over the last 100 years illustrates how ...
Breaking Biology News(10 mins):Genetics risk, prenatal smoking may predict behavioral problems 2In lab tests, the antimicrobial ingredient triclosan spurs growth of breast cancer cells 2Impact of whooping cough vaccination revealed 2
... The University of Utah is launching a six-year, $21.5 ... materials for uses ranging from faster computers and communications devices ... Center of Excellence in Materials Research and Innovation is being ... grant from the National Science Foundation (NSF), $6.5 million for ...
... reversible adhesives; tenaciously clinging barnacles; and surfaces that rub ... topics that will be presented at the AVS 58th ... place Oct. 30 - Nov. 4, 2011, at the ... press registration to journalists; see details below. Journalists may ...
... Three leading sci-tech experts described engineering trends for ... this summer at the Directors Guild in Los ... of Sciences (NAS) Science & Entertainment Exchange to ... and scientists that engage the public in television, ...
Cached Biology News:$21.5 million for materials research at the University of Utah 2$21.5 million for materials research at the University of Utah 3Media invited: AVS 58th International Symposium and Exhibition 2Media invited: AVS 58th International Symposium and Exhibition 3Media invited: AVS 58th International Symposium and Exhibition 4Media invited: AVS 58th International Symposium and Exhibition 5IEEE-USA/NAS Hollywood Forum describes engineering trends for entertainment industry professionals 2
... filter (S37100, Photographic Filters for Fluorescent ... for black-and-white photography of gels stained ... stain, the safer ethidium bromide alternative. ... filter is identical to the SYPRO ...
Enodgenous alkaline phosphotase inhibitor. Levamisole solution is supplied in concentrated form (20x). The final concentration of levamisole in the substrate solution will be 1 mM....
Several Pichia pastoris strains are available to allow you to optimize expression and recovery of your protein of interest. Table 1 provides information to help you choose the appropriate strain....
Standard 2" or 3" Plastic can be ordered with 81 or 100 cell dividers. Mini 2" Plastics Boxes come standard with 25 cell dividers. Plastic boxes can also be ordered with corresponding freezer racks...
Biology Products: